Last reviewed · How we verify
Piritetrate (LIRANAFTATE)
Piritetrate (generic name: LIRANAFTATE) is a drug. It is currently in Phase 2 development.
Piritetrate works by binding to a specific target, although the exact mechanism is currently unknown.
Piritetrate (LIRANAFTATE) is a small molecule modality with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. The approved indications for Piritetrate are also unknown. As a result, key safety considerations and generic manufacturers are also not available. Further research is needed to understand the pharmacology and clinical use of Piritetrate.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | LIRANAFTATE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells have locks on them, and Piritetrate has a key that fits into one of those locks. When it binds, it can either turn the lock to open the cell or block the lock to prevent something from getting in. However, the specific lock and key interaction for Piritetrate is still a mystery.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Piritetrate CI brief — competitive landscape report
- Piritetrate updates RSS · CI watch RSS
Frequently asked questions about Piritetrate
What is Piritetrate?
How does Piritetrate work?
What is the generic name of Piritetrate?
What development phase is Piritetrate in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing